Table 1.
Median age | 62 (37–92) |
Median follow-up (months) | 100 (66–131) |
FIGO Stage/substage, (N%) | |
Ib2 | 13 (14%) |
IIb | 65 (72%) |
IIIa/IIIb | 12 (13%) |
IVa | 1 (1%) |
Histology | |
Squamous carcinoma | 80 (88%) |
Adenocarcinoma | 8 (9%) |
Adenosquamous carcinoma | 3 (3%) |
Treatment modalities | |
Type 1 (EBRT Dose 50/45 Gy + ICRT) | 75 (82%) |
Type 2 (EBRT Dose 45/60 Gy + ICRT) | 9 (10%) |
Extended radiation field | 7 (8%) |